1
|
Dalton KP, Alvarado C, Reytor E, del Carmen Nuñez M, Podadera A, Martínez-Alonso D, Alonso JMM, Nicieza I, Gómez-Sebastián S, Dalton RM, Parra F, Escribano JM. Chimeric VLPs Bearing VP60 from Two Serotypes of Rabbit Haemorrhagic Disease Virus Are Protective against Both Viruses. Vaccines (Basel) 2021; 9:vaccines9091005. [PMID: 34579243 PMCID: PMC8472679 DOI: 10.3390/vaccines9091005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 08/26/2021] [Accepted: 08/31/2021] [Indexed: 11/24/2022] Open
Abstract
The VP60 capsid protein from rabbit haemorrhagic disease virus (RHDV), the causative agent of one of the most economically important disease in rabbits worldwide, forms virus-like particles (VLPs) when expressed using heterologous protein expression systems such as recombinant baculovirus, yeasts, plants or mammalian cell cultures. To prevent RHDV dissemination, it would be beneficial to develop a bivalent vaccine including both RHDV GI.1- and RHDV GI.2-derived VLPs to achieve robust immunisation against both serotypes. In the present work, we developed a strategy of production of a dual-serving RHDV vaccine co-expressing the VP60 proteins from the two RHDV predominant serotypes using CrisBio technology, which uses Tricholusia ni insect pupae as natural bioreactors, which are programmed by recombinant baculovirus vectors. Co-infecting the insect pupae with two baculovirus vectors expressing the RHDV GI.1- and RHDV GI.2-derived VP60 proteins, we obtained chimeric VLPs incorporating both proteins as determined by using serotype-specific monoclonal antibodies. The resulting VLPs showed the typical size and shape of this calicivirus as determined by electron microscopy. Rabbits immunised with the chimeric VLPs were fully protected against a lethal challenge infection with the two RHDV serotypes. This study demonstrates that it is possible to generate a dual cost-effective vaccine against this virus using a single production and purification process, greatly simplifying vaccine manufacturing.
Collapse
Affiliation(s)
- Kevin P. Dalton
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - Carmen Alvarado
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Edel Reytor
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Maria del Carmen Nuñez
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Ana Podadera
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - Diego Martínez-Alonso
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Jose Manuel Martin Alonso
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - Ines Nicieza
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - Silvia Gómez-Sebastián
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Romy M. Dalton
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Francisco Parra
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - José M. Escribano
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
- Correspondence:
| |
Collapse
|
2
|
González-Martínez J, Cwetsch AW, Martínez-Alonso D, López-Sainz LR, Almagro J, Melati A, Gómez J, Pérez-Martínez M, Megías D, Boskovic J, Gilabert-Juan J, Graña-Castro O, Pierani A, Behrens A, Ortega S, Malumbres M. Deficient adaptation to centrosome duplication defects in neural progenitors causes microcephaly and subcortical heterotopias. JCI Insight 2021; 6:e146364. [PMID: 34237032 PMCID: PMC8409993 DOI: 10.1172/jci.insight.146364] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 07/07/2021] [Indexed: 11/17/2022] Open
Abstract
Congenital microcephaly (MCPH) is a neurodevelopmental disease associated with mutations in genes encoding proteins involved in centrosomal and chromosomal dynamics during mitosis. Detailed MCPH pathogenesis at the cellular level is still elusive, given the diversity of MCPH genes and lack of comparative in vivo studies. By generating a series of CRISPR/Cas9-mediated genetic KOs, we report here that — whereas defects in spindle pole proteins (ASPM, MCPH5) result in mild MCPH during development — lack of centrosome (CDK5RAP2, MCPH3) or centriole (CEP135, MCPH8) regulators induces delayed chromosome segregation and chromosomal instability in neural progenitors (NPs). Our mouse model of MCPH8 suggests that loss of CEP135 results in centriole duplication defects, TP53 activation, and cell death of NPs. Trp53 ablation in a Cep135-deficient background prevents cell death but not MCPH, and it leads to subcortical heterotopias, a malformation seen in MCPH8 patients. These results suggest that MCPH in some MCPH patients can arise from the lack of adaptation to centriole defects in NPs and may lead to architectural defects if chromosomally unstable cells are not eliminated during brain development.
Collapse
Affiliation(s)
- José González-Martínez
- Cell Division and Cancer group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Andrzej W Cwetsch
- Cell Division and Cancer group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.,Imagine Institute of Genetic Diseases, University of Paris, Paris, France.,Institute of Psychiatry and Neuroscience of Paris, INSERM U-1266, University of Paris, Paris, France
| | - Diego Martínez-Alonso
- Cell Division and Cancer group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Luis R López-Sainz
- Cell Division and Cancer group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Jorge Almagro
- Adult Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
| | - Anna Melati
- Cell Division and Cancer group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | | | | | | | - Javier Gilabert-Juan
- Cell Division and Cancer group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.,University of Paris, NeuroDiderot, Inserm, Paris, France
| | | | - Alessandra Pierani
- Imagine Institute of Genetic Diseases, University of Paris, Paris, France.,Institute of Psychiatry and Neuroscience of Paris, INSERM U-1266, University of Paris, Paris, France
| | - Axel Behrens
- Adult Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.,Faculty of Life Sciences, King's College London, Guy's Campus, London, United Kingdom
| | | | - Marcos Malumbres
- Cell Division and Cancer group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| |
Collapse
|
3
|
Abstract
Proper progression throughout the cell division cycle depends on the expression level of a family of proteins known as cyclins, and the subsequent activation of cyclin-dependent kinases (Cdks). Among the numerous members of the mammalian cyclin family, only a few of them, cyclins A, B, C, D and E, are known to display critical roles in the cell cycle. These functions will be reviewed here with a special focus on their relevance in different cell types in vivo and their implications in human disease.
Collapse
Affiliation(s)
- Diego Martínez-Alonso
- Cell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO) Madrid, Spain.
| | - Marcos Malumbres
- Cell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO) Madrid, Spain.
| |
Collapse
|
4
|
Barrado-Gil L, Galindo I, Martínez-Alonso D, Viedma S, Alonso C. The ubiquitin-proteasome system is required for African swine fever replication. PLoS One 2017; 12:e0189741. [PMID: 29244872 PMCID: PMC5731689 DOI: 10.1371/journal.pone.0189741] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Accepted: 11/30/2017] [Indexed: 01/28/2023] Open
Abstract
Several viruses manipulate the ubiquitin-proteasome system (UPS) to initiate a productive infection. Determined viral proteins are able to change the host’s ubiquitin machinery and some viruses even encode their own ubiquitinating or deubiquitinating enzymes. African swine fever virus (ASFV) encodes a gene homologous to the E2 ubiquitin conjugating (UBC) enzyme. The viral ubiquitin-conjugating enzyme (UBCv1) is expressed throughout ASFV infection and accumulates at late times post infection. UBCv is also present in the viral particle suggesting that the ubiquitin-proteasome pathway could play an important role at early ASFV infection. We determined that inhibition of the final stage of the ubiquitin-proteasome pathway blocked a post-internalization step in ASFV replication in Vero cells. Under proteasome inhibition, ASF viral genome replication, late gene expression and viral production were severely reduced. Also, ASFV enhanced proteasome activity at late times and the accumulation of polyubiquitinated proteins surrounding viral factories. Core-associated and/or viral proteins involved in DNA replication may be targets for the ubiquitin-proteasome pathway that could possibly assist virus uncoating at final core breakdown and viral DNA release. At later steps, polyubiquitinated proteins at viral factories could exert regulatory roles in cell signaling.
Collapse
Affiliation(s)
- Lucía Barrado-Gil
- Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, INIA, Madrid, Spain
| | - Inmaculada Galindo
- Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, INIA, Madrid, Spain
| | - Diego Martínez-Alonso
- Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, INIA, Madrid, Spain
| | - Sergio Viedma
- Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, INIA, Madrid, Spain
| | - Covadonga Alonso
- Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, INIA, Madrid, Spain
- * E-mail:
| |
Collapse
|
5
|
López-Vidal J, Gómez-Sebastián S, Bárcena J, Nuñez MDC, Martínez-Alonso D, Dudognon B, Guijarro E, Escribano JM. Improved Production Efficiency of Virus-Like Particles by the Baculovirus Expression Vector System. PLoS One 2015; 10:e0140039. [PMID: 26458221 PMCID: PMC4601761 DOI: 10.1371/journal.pone.0140039] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2015] [Accepted: 09/21/2015] [Indexed: 12/29/2022] Open
Abstract
Vaccines based on virus-like particles (VLPs) have proven effective in humans and animals. In this regard, the baculovirus expression vector system (BEVS) is one of the technologies of choice to generate such highly immunogenic vaccines. The extended use of these vaccines for human and animal populations is constrained because of high production costs, therefore a significant improvement in productivity is crucial to ensure their commercial viability. Here we describe the use of the previously described baculovirus expression cassette, called TB, to model the production of two VLP-forming vaccine antigens in insect cells. Capsid proteins from porcine circovirus type 2 (PCV2 Cap) and from the calicivirus that causes rabbit hemorrhagic disease (RHDV VP60) were expressed in insect cells using baculoviruses genetically engineered with the TB expression cassette. Productivity was compared to that obtained using standard counterpart vectors expressing the same proteins under the control of the polyhedrin promoter. Our results demonstrate that the use of the TB expression cassette increased the production yields of these vaccine antigens by around 300% with respect to the standard vectors. The recombinant proteins produced by TB-modified vectors were fully functional, forming VLPs identical in size and shape to those generated by the standard baculoviruses, as determined by electron microscopy analysis. The use of the TB expression cassette implies a simple modification of the baculovirus vectors that significantly improves the cost efficiency of VLP-based vaccine production, thereby facilitating the commercial viability and broad application of these vaccines for human and animal health.
Collapse
Affiliation(s)
- Javier López-Vidal
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Silvia Gómez-Sebastián
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Juan Bárcena
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, Madrid, Spain
| | - Maria del Carmen Nuñez
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Diego Martínez-Alonso
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Benoit Dudognon
- Alternative Gene Expression S.L. (ALGENEX), Edificio de empresas, Campus Montegancedo (Universidad Politécnica de Madrid), Pozuelo de Alarcón, Madrid, Spain
| | - Eva Guijarro
- Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Autovia A6 Km 7, Madrid, Spain
| | - José M. Escribano
- Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Autovia A6 Km 7, Madrid, Spain
- * E-mail:
| |
Collapse
|